Abstract
The US FDA granted approval for crizotinib as the first-line treatment for patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase rearranged metastatic non-small-cell lung cancer, on November 20, 2013. Crizotinib is a customized and improved therapeutic option for patients with non-small-cell lung cancer that enhances overall survival without increasing toxicity. In the future, new targeted therapies may achieve additional indications for treating patients with lung cancer. This article summarizes data from crizotinib studies.
| Original language | English |
|---|---|
| Pages (from-to) | 375-385 |
| Number of pages | 11 |
| Journal | Expert Review of Anticancer Therapy |
| Volume | 15 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 1 2015 |
ASJC Scopus Subject Areas
- Oncology
- Pharmacology (medical)
Keywords
- anaplastic lymphoma kinase
- c-ros1
- crizotinib
- echinoderm microtubule-associated protein-like 4
- met/hepatocyte growth factor receptor
- non-small-cell lung cancer
- Crizotinib
- Humans
- Survival Rate
- Pyrazoles/adverse effects
- Molecular Targeted Therapy
- Pyridines/adverse effects
- Neoplasm Metastasis
- Protein Kinase Inhibitors/adverse effects
- Animals
- Gene Rearrangement
- Lung Neoplasms/drug therapy
- Carcinoma, Non-Small-Cell Lung/drug therapy
- Oncogene Proteins, Fusion/genetics
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS